

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:       Turnbull, et al.

International App. No.:   PCT/US2005/007245

Group Art Unit:

International Filing Date: March 3, 2005

Examiner:

For:                       ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR  
                              MUDULATORS

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed  
☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_, (37 CFR 1.98(d))  
☒ A copy of the International Search Report which issued on International Application No. PCT/US2005/007245 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒       The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐       **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

- B. ☐       The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:  
          (1)     a final action under § 1.113 or  
          (2)     a notice of allowance under § 1.311,  
          whichever occurs first.

- ☐     Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐     Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Jennifer L. Fox  
Attorney for Applicant  
Registration No. 52,218

Date: 1 Sept 06

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-6334

Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.</b> <b>PR60689USW</b>		<b>INTERNATIONAL APP. NO.</b> <b>PCT/US2005/007245</b>	
				<b>APPLICANT</b> <b>Turnbull et al.</b>			
				<b>INTERNATIONAL FILING DATE</b> <b>3/3/05</b>		<b>GROUP</b>	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
		2002/099096	7/25/02	Dalton, et al.			
Continue on page _____							
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
		98/22441	5/28/98	PCT			
		98/22493	5/28/98	PCT			
Continue on page _____							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
		F.Z. Galin et al., "Synthesis of N-phenylvaline derivatives under phase transfer catalysis," <u>Russian Journal of Organic Chemistry</u> , V34 N6, 1998, page 899.					
		J. Saravanan et al., "RN-244070-45-5, <u>Indian Drugs</u> ," V36 N3, 1999, pp. 192-195.					
		D.R. Tortolani et al., "A convenient synthesis to N-aryl-substituted 4-piperidones," <u>Organic Letters</u> , VI N8, 1999, pp. 1261-1262.					
		H.F. Dovey et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>Journal of Neurochemistry</u> , V76, N1, 2001, pp. 173-181.					
		C.S. Dunkley et al., "Synthesis and biological evaluation of a novel phenyl-substituted sydnone series a spotential antitumor agents," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , V13 N17, 2003, pp. 2899-2901.					
		H. Waga et al., "Synthesis of plant growth substances," <u>Noguku Kenkyu</u> , V. 47, 1959, pp. 111-113.					
		C.B. Das et al., "Polyaniline supported cobalt (II)-salen catalyst;; one -pot synthesis of beta-phenylisoserine derivatives from cinnamoyl amide," <u>Tetrahedron Letters</u> , V38 N16, 1997, pp. 2903-2906.					
Continue on page _____							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>		
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							